Previous studies found that in human SLE, miR-7 inhibitors directly targeted the PTEN 3′-UTR, inhibited PTEN mRNA and protein expression, and inappropriate activation of the AKT signalling pathway in lupus B cells (Wu et al., 2014). The gene discussed is AKT1; the disease is systemic lupus erythematosus.